Certain HPV16 antibodies may predict oropharyngeal cancer survival
the ONA take:
Certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved survival rates among patients with HPV-related oropharyngeal carcinoma, according to a new study.
For the study, researchers analyzed blood samples from 209 patients with previously untreated oropharyngeal carcinoma. Of those, 96 had confirmed HPV-positive disease. Samples were screened for HPV16 antibodies E1, E4-7, L1, L2, and the N-terminal and C-terminal fragments of E2.
Results showed that patients with any of the E antibodies had improved overall and progression-free survival versus those who tested negative for the antibodies. HPV-positive patients who tested positive for NE2, E1, or E6 antibodies also had a reduced mortality and disease progression risk.
Researchers found no survival advantage for people who tested positive for L antibodies.
Clinical trials are currently ongoing to evaluate whether vaccines can stimulate these antibodies to improve outcomes in patients with HPV-related cancers.
Certain HPV-16 antibodies in the blood associated with improved survival in HPV-related oropharyngeal carcinoma.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|